News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Avant Immunotherapeutics (AVAN) Data Shows Brain Cancer Vaccine Doubles Survival


6/3/2008 6:15:36 AM

CHICAGO -(Dow Jones)- Two small midstage studies of an experimental therapy being developed by Avant Immunotherapeutics Inc. (AVAN) and Pfizer Inc. (PFE) showed positive results in an aggressive form of brain cancer. The results come less than two months after Pfizer cut a deal to buy the exclusive worldwide license to CDX-110 by paying $40 million and investing $10 million in Avant, as well as promising to pay $390 million in potential milestone payments and double-digit royalties.

Read at Reuters
Read at Pharma Times [Free Reg Req'd]
Read at CNN Money
Read at Market Watch
Read at AP

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES